# ASC36

About 3 search results

Sort by Date

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist

Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

About Storm Media

The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.

The Storm Media (Chinese)

The Storm Media Japan

The Journalist

1% STYLE

Neihu District, Ruiguang Road, Lane 513, No. 37, 4F. Taipei, 114.

Stay True・Look Beyond

Version: 20261007-145718